Shopping Cart 0
Cart Subtotal
USD 0

Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The company's major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11

Nicox Enters into Agreement with Ironwood Pharma 12

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13

Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14

AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15

Licensing Agreements 17

Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17

Equity Offering 18

Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18

Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19

Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For USD 146 Million 21

Ironwood Pharma Completes Public Offering Of Common Stock For USD 91 Million 23

Debt Offering 25

Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25

Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26

Ironwood Pharma Completes Private Placement Of Notes Due 2024 For USD 175 Million 27

Ironwood Pharmaceuticals Inc-Key Competitors 29

Ironwood Pharmaceuticals Inc-Key Employees 30

Ironwood Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Aug 06, 2018: Ironwood Pharmaceuticals provides second quarter 2018 investor update 32

May 01, 2018: Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update 37

Feb 15, 2018: Ironwood Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 39

Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 42

Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 47

May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 49

Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 51

Corporate Communications 55

Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 55

Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 56

Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 57

Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 58

Government and Public Interest 59

May 01, 2018: Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business 59

Clinical Trials 61

Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718 61

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018 62

May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018 64

Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease 66

Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects 67

Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease 69

May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 71

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 72

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017 73

Other Significant Developments 74

May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 74

Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 75

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11

Nicox Enters into Agreement with Ironwood Pharma 12

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13

Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14

AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15

Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17

Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18

Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19

Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For USD 146 Million 21

Ironwood Pharma Completes Public Offering Of Common Stock For USD 91 Million 23

Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25

Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26

Ironwood Pharma Completes Private Placement Of Notes Due 2024 For USD 175 Million 27

Ironwood Pharmaceuticals Inc, Key Competitors 29

Ironwood Pharmaceuticals Inc, Key Employees 30

Ironwood Pharmaceuticals Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Ironwood Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The company's major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11

Nicox Enters into Agreement with Ironwood Pharma 12

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13

Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14

AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15

Licensing Agreements 17

Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17

Equity Offering 18

Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18

Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19

Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For USD 146 Million 21

Ironwood Pharma Completes Public Offering Of Common Stock For USD 91 Million 23

Debt Offering 25

Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25

Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26

Ironwood Pharma Completes Private Placement Of Notes Due 2024 For USD 175 Million 27

Ironwood Pharmaceuticals Inc-Key Competitors 29

Ironwood Pharmaceuticals Inc-Key Employees 30

Ironwood Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Aug 06, 2018: Ironwood Pharmaceuticals provides second quarter 2018 investor update 32

May 01, 2018: Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update 37

Feb 15, 2018: Ironwood Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 39

Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 42

Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 47

May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 49

Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 51

Corporate Communications 55

Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 55

Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 56

Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 57

Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 58

Government and Public Interest 59

May 01, 2018: Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business 59

Clinical Trials 61

Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718 61

Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018 62

May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018 64

Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease 66

Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects 67

Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease 69

May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 71

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 72

Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017 73

Other Significant Developments 74

May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 74

Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 75

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77


List Of Figure

List of Figures

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11

Nicox Enters into Agreement with Ironwood Pharma 12

Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13

Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14

AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15

Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17

Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18

Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19

Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For USD 146 Million 21

Ironwood Pharma Completes Public Offering Of Common Stock For USD 91 Million 23

Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25

Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26

Ironwood Pharma Completes Private Placement Of Notes Due 2024 For USD 175 Million 27

Ironwood Pharmaceuticals Inc, Key Competitors 29

Ironwood Pharmaceuticals Inc, Key Employees 30

Ironwood Pharmaceuticals Inc, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Ironwood Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.